N-(2,5-二氯苄基)-N-甲胺 | 90390-16-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2,5-二氯苄基)-N-甲胺
• 中文别名: 2,5-二氯-N-甲基苯甲胺
• 英文名称: N-(2,5-Dichlorobenzyl)-N-methylamine
• 英文别名: 1-(2,5-dichlorophenyl)-N-methylmethanamine
• CAS: 90390-16-2
• 化学式: C₈H₉Cl₂N
• 分子量: 190.072
• InChiKey: MBWHXHJPISASFP-UHFFFAOYSA-N

物化性质

• 沸点：
  238.4±25.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为产物：
  描述：

  (2,5-dichloro-benzylidene)-methyl-amine 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 生成 N-(2,5-二氯苄基)-N-甲胺
  参考文献：
  名称：

  Benzylamines: synthesis and evaluation of antimycobacterial properties

  摘要：

  The synthesis of benzylamines with various N-alkyl chains and substituents in the aromatic system as well as their evaluation on Mycobacterium tuberculosis H 37 Ra are described. The most active compounds in this test, N-methyl-3-chlorobenzylamine (19, MIC 10.2 micrograms/mL), N-methyl-3,5-dichlorobenzylamine (93, MIC 10.2 micrograms/mL), and N-butyl-3,5-difluorobenzylamine (103, MIC 6.4 micrograms/mL), also exhibited a marked inhibitory effect on Mycobacterium marinum and Mycobacterium lufu used for the determination of antileprotic properties. The combinations of 93 with aminosalicylic acid, streptomycin, or dapsone exert marked supra-additive effects on M. tuberculosis H 37 Ra.

  DOI：

  10.1021/jm00375a005

文献信息

• [EN] SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF<br/>[FR] DERIVE D'ACIDE ARYLALCANOIQUE SUBSTITUE ET SON UTILISATION
  申请人：ASAHI KASEI PHARMA CORP

  公开号：WO2005016862A1

  公开（公告）日：2005-02-24

  A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.

  化合物的化学式为（I）。在该式中，Link代表一个由1至3个碳原子组成的饱和或不饱和直链烃链，芳环（E）中的C2至C6独立代表构成环的碳原子，构成环的碳原子中的一个可以被V取代，V代表氮原子，或者被Zx取代的碳原子，Zx代表由1至4个碳原子组成的饱和烷基基团等，Rs代表-D-Rx等，D代表单键、氧原子等，Rx代表由3至8个碳原子组成的饱和烷基基团等，AR代表部分不饱和或完全不饱和的紧凑双环碳环或杂环，Y代表氢原子、由1至4个碳原子组成的低烷基基团等，或其盐。提供了一种具有抑制前列腺素产生和抑制白三烯产生作用的化合物。
• PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140243338A1

  公开（公告）日：2014-08-28

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些药物组合物治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• [EN] TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS INHIBITEUR DE TGFBETAR1-ANTICORPS ANTI-ASGR ET UTILISATIONS ASSOCIÉES
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2021072203A1

  公开（公告）日：2021-04-15

  Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGFβR1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.

  本发明揭示了用于治疗肝病（如肝癌和肝纤维化）的各种共轭物和其组合物。这些组合物包括共轭物，其中共轭物由特异于ASGR1或ASGR2的抗体或抗体构造物通过连接剂连接到TGFβR1抑制剂上。此外，还提供了这些共轭物和组合物的制备方法。
• [EN] ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF<br/>[FR] INHIBITEURS D'ALK5, CONJUGUÉS ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2021011834A1

  公开（公告）日：2021-01-21

  ALK5 inhibitor compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in the treating of cancer and fibrosis and modulating ALK5. Additionally, compounds incorporated into a conjugate with an antibody construct are described herein.

  本文披露了用于治疗疾病（如癌症）的ALK5抑制剂化合物、结合物和药物组合物。所披露的化合物在治疗癌症和纤维化以及调节ALK5等方面非常有用。此外，本文还描述了与抗体构造物结合的化合物。
• 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
  申请人：——

  公开号：US20040242592A1

  公开（公告）日：2004-12-02

  The present invention relates to piperazine derivatives of formula (I), wherein R represents halogen, C 1-4 alkyl, trifluoromethoxy or trifluoromethyl; R 1 is trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, halogen or trifluoromethoxy; R 2 is hydrogen, C 1-4 alkyl or C 2-6 alkenyl; R 3 represents hydrogen or C 1-4 alkyl; n and m are independently 0 or an integer from 1 to 3; and pharmaceutically acceptable salts and solvates thereof, process for their preparation and their use in the treatment of condition mediated by tachykinins and/or by selective inhibition of the serotonin reuptake transporter protein. 1

  本发明涉及式（I）的哌嗪衍生物，其中R代表卤素、C1-4烷基、三氟甲氧基或三氟甲基；R1为三氟甲基、C1-4烷基、C1-4烷氧基、卤素或三氟甲氧基；R2为氢、C1-4烷基或C2-6烯基；R3代表氢或C1-4烷基；n和m分别独立地为0或1到3的整数；以及其药学上可接受的盐和溶剂合物，它们的制备方法以及它们在通过选择性抑制血清素再摄取转运蛋白和/或介导催吐肽的疾病治疗中的用途。